Corbion is a specialty chemicals company focused on sustainable food-ingredient solutions, natural preservation, and nutrition. The company produces lactic acid and its derivatives, food preservation solutions, functional ingredient systems, and algae-derived nutritional ingredients. Its products serve markets including food, animal nutrition, home and personal care, pharmaceuticals, electronics, medical devices, and bioplastics. Corbion utilizes fermentation and preservation technology to help customers develop safe, longer-lasting food products and functional blends. The company offers tools such as the Listeria Control Model for predictive food safety modeling in ready-to-eat foods. Corbion has been active in the industry for more than a century, combining scientific innovation with application development to address formulation challenges for food and nutrition brands.

Summarised from the company's own disclosures, fiscal year ended Dec 2024

Industry Specialty Chemicals Homepage corbion.com
Sector Basic Materials IR page corbion.com/investor-relations
Tags
lactic acid, food preservation, fermentation, functional ingredients, algae ingredients, bioplastics, animal nutrition, pharmaceuticals, medical devices, personal care, Listeria Control Model
Press page corbion.com/media/press-release

Metrics

Valuation  
Market cap € 1.055B
Market cap (USD) $ 1.166B
P/E 14.11
PEG —
P/BV 1.42
P/S 1.07
P/OCF 9.68
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 9.9%
ROI 10.2%
ROIC 12.5%
Profit margin 5.9%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) -6.0%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock Yes
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score 6.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009
Revenue 1.267B 1.288B 1.444B 1.458B 1.071B 986.5M 976.4M 897.2M 891.7M 911.3M 918.3M 770.1M 743.6M 753.7M — 2.99B 2.556B
Net profit 74.8M 192.2M 72.9M 90M 78.3M 73.1M 25.8M — — — — — — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009
Share price 18.2 20.67 28.54 — 44.49 44.49 25.56 — — — — — — — — — —
Price performance 12m -0.12 -0.28 — — 0 0.74 — — — — — — — — — — —

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (EUR) — 124M 124M 163M 211M 201M 173M 175M
↳ YoY growth -0.4% +31.9% +29.0% -4.6% -13.9% +1.1%
↳ 5y CAGR +6.9% +7.2%
Borrowings, current (EUR) — 170M 42.4M 74.7M 310M 356M 188M 86.6M
Borrowings, non-current (EUR) — 113M 240M 359M 376M 365M 262M 313M
Lease liabilities (EUR) — 66.2M 53.9M 69.4M 73.5M 64.9M 59M 46.9M
Cash and deposits (EUR) 47.1M 45.7M 51.6M 42.2M 58.2M 70.2M 49.3M 44.7M
Right-of-use assets (EUR) — 64.8M 51.1M 66.1M 68.4M 59M 54.1M 42.3M
Net debt (borrowings + leases - cash) (EUR) — 303M 284M 461M 701M 715M 460M 402M
Cash flow detail
Operating cash flow (EUR) — 114M 109M 22.4M 39M 165M 184M 161M
Change in receivables (cash effect) (EUR) — -2.6M -10.7M -33.2M -39M 4.7M 6.2M -14.2M
Change in inventories (cash effect) (EUR) — -3.5M -17.2M -54.4M -90.4M 61.5M -5.2M -700,000
Change in payables (cash effect) (EUR) — 4.9M 13.5M 25.7M 14.6M -41.9M 6.4M 10.1M
Dividends paid (cash effect) (EUR) — -32.9M -33M -33M -33M -33.1M -41.9M -37.2M
Interest paid (cash effect) (EUR) — -10M -10.8M -13M -18.1M -27.4M -25.1M -15.4M
Income taxes paid (cash effect) (EUR) — -4M -10.7M -25.5M -18.3M -11.7M -15.9M -15.7M
Share-based compensation (EUR) — 4M 3.9M 3.5M 4.8M 4.1M 4.7M 5.2M
Operating cash flow before change in receivables (EUR) — 117M 120M 55.6M 78M 161M 178M 175M
Income detail
Research and development expense (EUR) — 48.1M 37.2M 65.8M 47.2M 46M 48M 42.8M
↳ 5y CAGR 0.0% +2.8%
Total comprehensive income (EUR) — 38.7M 17.2M 70.7M 101M 40.9M 194M 13.2M
Comprehensive income to owners (EUR) — 38.7M 17.2M 70.7M 101M 40.9M 194M 13.2M
Reported May 20, 2021 May 20, 2021 May 20, 2021 Mar 16, 2022 Mar 22, 2023 Mar 18, 2024 Apr 15, 2025 Mar 16, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

October 28, 2026 07:00 CET | Source: Corbion


Corbion, the Amsterdam-listed sustainable ingredients company that champions preservation through the application of science, today publishes its results for the first nine months and third quarter of 2026.

Key highlights first nine months 2026:

Organic sales growth: +3.9% (Q3: +7.6%)
- Volume/mix: +5.3% (Q3: +7.9%)
-Price:               -1.4% (Q3: -0.3%)
Sales: € 971.6 million (Q3: € 340.5 million)
Adjusted EBITDA: € 152.9 million (Q3: € 64.1 million)
Adjusted EBITDA organic growth: +3.5% (Q3: +28.2%)
Operating profit: € 81.4 million
Continued positive volume/mix development in both segments
- Very strong Q3 volume/mix development in Health & Nutrition
Free Cash Flow: € 57 million
Corbion discontinues PLA divestment process
FY 2026 guidance maintained
€ million YTD 2026 YTD 2025 YTD growth YTD Organic growth Q3 2026 Q3 2025 Q3 growth Q3 Organic growth
Sales 971.6 957.2 +1.5% +3.9% 340.5 311.6 +9.3% +7.6%
Adjusted EBITDA 152.9 156.3 -2.2% +3.5% 64.1 49.7 +29.0% +28.2%
Adj. EBITDA margin (%) 15.7% 16.3% -60 bps 18.8% 15.9% +290 bps
Operating profit 81.4 91.4 -10.9% -2.0% 39.3 27.9 +40.9% +39.1%

Commenting on today’s results, Olivier Rigaud, CEO, stated: “I am proud to report that our team delivered strong results, reflecting the high demand for our portfolio and disciplined execution across the businesses. Organic sales growth was driven by continued positive volume/mix development in both segments. Sales strength was broad-based but especially pronounced in Health & Nutrition due to the phasing of Nutrition volumes from the first half as anticipated.

In Functional Ingredients & Solutions, demand for natural preservation solutions in the Food business remained healthy, and Biochemicals continued its strong growth trajectory from H1. In Health & Nutrition, Nutrition delivered strong growth, supported by very strong volume/mix growth. Higher fish oil prices contributed to increased omega-3 DHA prices in the quarter positively impacting the mix component in the strong volume/mix result in the segment.

Adjusted EBITDA margins improved strongly in the quarter, supported by ongoing cost-reduction initiatives, operational efficiencies, and higher omega-3 DHA prices. We also delivered strong free cash flow generation, demonstrating the quality of our earnings and the strength of our business model.

While the process to sell our interest in the TotalEnergies Corbion joint venture attracted interest from potential buyers, the proposals we received did not adequately reflect the business’s value, strategic position, and long-term potential. We have therefore concluded that continuing to develop the business is the best way to maximize shareholder value.

Based on our strong year-to-date performance and visibility into the fourth-quarter orderbook, we maintain our full-year 2026 guidance.”

October 20, 2026 15:47 CET | Source: Corbion


Corbion will hold an Extraordinary General Meeting of Shareholders (EGM) on 2 December 2026.

The sole agenda item is the appointment of Mr. Alexander (Xander) Wessels as member of the Supervisory Board.

The full EGM agenda together with explanatory notes is available on Corbion's website under Investor relations --> Shareholder information --> Shareholder meetings.

October 02, 2026 07:00 CET | Source: Corbion


Corbion today announces that CEO Olivier Rigaud has informed the Supervisory Board that he will not seek a third term as CEO when his current appointment expires at the Annual General Meeting of Shareholders (AGM) on 12 May 2027.

After eight years as CEO, Olivier believes the end of his current term will be the right moment to hand over leadership of the company. During his tenure, he has guided Corbion through a period of significant transformation and strengthened the company's position for future growth and value creation. Olivier will remain fully committed to Corbion and continue to lead the company until the AGM on 12 May 2027, with a continued focus on improving performance, strengthening execution and advancing the company's strategic priorities.

The Supervisory Board has initiated a succession process to identify Corbion's next CEO. The Supervisory Board is confident that the planned transition timeline provides ample opportunity to ensure continuity of leadership, a smooth handover, and continued focus on delivering long term value for customers, employees, shareholders and other stakeholders.

In addition, the Supervisory Board intends to nominate Alexander (Xander) Wessels for appointment as a member of the Supervisory Board at an Extraordinary General Meeting.

Xander Wessels, a Dutch national, brings extensive experience in the life sciences, specialty chemicals and food ingredients industries, with deep expertise in strategy, operational excellence, international business leadership and value creation. Throughout his career, he has held a number of senior leadership positions, including Chief Executive Officer of Caldic, Chief Executive Officer of Archroma, and President and Chief Executive Officer of DSM Pharmaceutical Products. Earlier in his career, he also held senior leadership roles within DSM and Campina. Currently, he serves as Chair of the Supervisory Board of NRG PALLAS and Chair of Enza Zaden, and is a member of the Board of Directors of Archroma.

The Supervisory Board believes that Mr. Wessels' experience in leading international B2B companies, driving transformation and operational performance, and serving on supervisory boards will be highly valuable as Corbion continues to execute BRIGHT 2030, strengthen performance and create long-term value for stakeholders.

Prompts

Corbion N.V. (ticker CRBN), listed in Netherlands.

ETFs Holding Corbion N.V.

ETF Weight in ETF Shares Market value As of
DISV 0.08% 143,705 $ 4.227M Nov 12, 2026
DFIS 0.05% 101,553 $ 2.987M Nov 12, 2026
AVDV 0.04% 286,927 $ 8.291M Nov 16, 2026
AVDS 0.04% 4,854 $ 140.269K Nov 16, 2026
DXIV 0.04% 2,894 $ 85.126K Nov 12, 2026
AVDE 0.02% 119,155 $ 3.443M Nov 16, 2026
AVSD 0.02% 3,196 $ 92.357K Nov 16, 2026
DFSI 0.02% 6,148 $ 180.842K Nov 12, 2026
DFIC 0.01% 67,507 $ 1.986M Nov 12, 2026
DFAX 0.01% 43,731 $ 1.286M Nov 12, 2026
DFAI 0.01% 48,056 $ 1.414M Nov 12, 2026